Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study
| Autor: | Alexandre Holthausen Campos, Elaine Maria Frade Costa, Bruno Caramelli, Nidia Celeste Horie, Marcio C. Mancini, Andressa Heimbecher Soares, Lucas Augusto Piccinin Chiang, Mariana Gomes Matheus, Fernanda Agostini Rocha, Cintia Cercato, Luciana Cavalheiro Marti |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty DIABETES MELLITUS Endocrinology Diabetes and Metabolism Medicine (miscellaneous) 030209 endocrinology & metabolism Hematocrit Placebo Clomiphene 03 medical and health sciences 0302 clinical medicine Sex hormone-binding globulin Double-Blind Method Internal medicine medicine Humans Obesity 030219 obstetrics & reproductive medicine Nutrition and Dietetics medicine.diagnostic_test biology business.industry Hypogonadism Estrogen Antagonists Endocrinology Blood chemistry Lean body mass biology.protein Luteinizing hormone Lipid profile business Body mass index |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| ISSN: | 1476-5497 |
| Popis: | Obesity causes secondary hypogonadism (HG) in men. Standard testosterone (T) replacement therapy improves metabolic parameters but leads to infertility. To evaluate clomiphene citrate (CC) treatment of adult men with male obesity-associated secondary hypogonadism (MOSH). Single-center, randomized, double-blind, placebo-controlled trial. Seventy-eight men aged 36.5 ± 7.8 years with a body mass index (BMI) > 30 kg/m2, total testosterone (TT) ≤ 300 ng/dL, and symptoms in the ADAM questionnaire. Random allocation to receive 50 mg CC or placebo (PLB) for 12 weeks. (1) Clinical features: ADAM and sexual behavior questionnaires; (2) hormonal profile: serum TT, free T, estradiol (E2), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex hormone-binding globulin (SHBG); (3) body composition: BMI, waist circumference, and bioelectric impedance analysis; (4) metabolic profile: blood pressure, fasting blood glucose, HbA1c, insulin, HOMA-IR, and lipid profile; (5) endothelial function: flow-mediated dilation of the brachial artery, quantitative assessment of endothelial progenitor cells and serum sICAM-1, sVCAM-1, and selectin-sE levels; (6) safety aspects: hematocrit, serum prostate-specific antigen, International Prostate Symptom Score, and self-reported adverse effects. There was an improvement in one sexual complaint (weaker erections; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink